{"id":532,"slug":"johnson-johnson","name":"Johnson & Johnson","type":"organization","created_at":"2026-08-08T04:36:50.654279+00:00","hidden":0,"aliases":[],"episodes":[{"id":"ddcccdb3-5d21-4b97-bafb-aa0d6c46c24f","slug":"episode-eighty-two-the-next-big-thing-in-drugs-as","subject":"Episode Eighty Two: The Next Big Thing In Drugs; As If You Needed Another NYT Opinion; Experience This; The Value Of The Thing","title":"The Next Big Thing In Drugs; As If You Needed Another NYT Opinion; Experience This; The Value Of The Thing","publish_date":"2014-05-17T00:00:00+00:00","year":2014,"month":5,"season":null,"episode":82,"episode_label":"episode 82","canonical_url":"https://newsletter.danhon.com/archive/episode-eighty-two-the-next-big-thing-in-drugs-as/","is_premium":0,"word_count":2586,"context":" … the article is hilarious because it states that \"The company will start by copying Enbrel (an arthritis therapy by Amgen Inc.) and Remicade (<mark>Johnson & Johnson</mark>’s autoimmune disease … ","reading_minutes":13}]}